abstract: OBJECTIVE: To discuss the methods and effects of serial therapies oriented by surgery in the treatment of primary large @entity96 . METHODS: From January 1993 to June 1999, 191 @entity1 with large @entity96 were treated surgically. The size of @entity5 varied from 5.2 to 19.7 cm (mean 9.4 cm). Several types of liver resections were made in 121 @entity1 and as a supplement, cryosurgery was carried out for the remaining 70 @entity1 . Importable drug delivery system was instituted intraoperatively. Transcatheter @entity1416 ( @entity7312 30-60 mg, E-ADM 20-40 mg, CDDP 40-80 mg, @entity1139 10-20 mg, iodin oil 5-30 ml), percutaneous @entity1068 injection, bioimmunotherapy and traditional Chinese medicine were used pre- and post-operatively. CT angiography and CT during arterial portography were used to find satellite nodules. Early stage recurrences were predicted by AFPmRNA in peripheral blood. @entity1 -Pugh's classification plus branch chain @entity535 /aromatic @entity535 ratio ( @entity18200 /AAA) was adopted in evaluating pre-operative liver functions. RESULTS: Marked results were observed after serial treatments oriented by surgery. The 1-, 3- and 5-year survival rates in resection group were 75.8%, 45.6% and 30.4%, respectively. The 1- and 3-year survival rates in cryosurgery group were 63.2% and 37.0%. The operative mortality was 1.57%. Recurrence rates were 69.2% in AFPmRNA positive group and 33.3% in AFPmRNA negative group (P<0.05). The @entity18200 / @entity6285 ratio was lower than 1.5 in two @entity1 who died of @entity1578 after resection. CONCLUSIONS: Serial treatments with surgery as the chief modality gives satisfactory results in @entity1 with large primary @entity96 . This regimen should be regarded as a main strategy to deal with large @entity96 . AFPmRNA in the peripheral blood, signifying a recurrence, may become a new clinical parameter. The @entity18200 /AAA ratio plus @entity1 -Pugh's classification is able to evaluate more accurately liver function reserve before surgery.

title: Serial therapies oriented by surgery for large primary XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'patients']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver cancers', 'liver carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity1416 :: ('MESH:D020762', 'Disease') :: ['arterial chemo-embolization']

entities_list: @entity1578 :: ('MESH:D017093', 'Disease') :: ['hepatic failure']

answer: @entity96 :: (MESH:D008113,Disease) :: ['liver carcinoma']


abstract: BACKGROUND: Early pathogenetic events of @entity1931 may be overlooked in @entity1 with serologic markers of @entity1593 and normal intestinal mucosa by both conventional histology and immunohistochemistry. AIMS: To investigate if a submicroscopical damage of the absorptive cell surface was associated with developing @entity1593 . @entity1 AND METHODS: Duodenal biopsies of seven subjects with positive anti-endomysial antibodies and normal histology underwent ultrastructural evaluation of the epithelial surface by means of both scanning and transmission electron microscopy. Specimens of intestinal mucosa of 14 @entity1 with non-celiac conditions were used as controls. RESULTS: In four @entity1 , electron microscopy revealed alterations of the enterocyte brush border with a significant reduction of the height of microvilli. After several months, three of them had a second biopsy that eventually showed histological modifications suggestive of @entity1593 . In the other three @entity1 , no significant alteration of enterocyte ultrastructure was observed. One of them, rebiopsied after 12 months, still showed a normal duodenal histology. CONCLUSIONS: @entity1593 can be associated with 'minimal' mucosal changes not detectable with conventional light microscopy. @entity75 , which primarily involve microvillous structure, may imply a reduction of intestinal absorptive surface already in the latent stage of the disease.

title: XXXX and 'normal' histology: is the intestinal mucosa really normal?

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'PATIENTS']

entities_list: @entity1931 :: ('MESH:D006930', 'Disease') :: ['gluten intolerance']

entities_list: @entity1593 :: ('MESH:D002446', 'Disease') :: ['gluten sensitivity', 'celiac disease', 'Gluten sensitivity']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['Such lesions']

answer: @entity1593 :: (MESH:D002446,Disease) :: ['Gluten sensitivity']


abstract: OBJECTIVE: To summarize the geographical and temporal variations in incidence of @entity2615 in Europe, using the extensive data available from European general cancer registries, and consider these in light of recent trends in @entity1355 extraction, use and import in European countries. MATERIAL AND METHODS: The data were extracted from the European @entity5 Incidence and Mortality database (EUROCIM). The inclusion criteria was acceptance in Volume VII of @entity5 Incidence in Five Continents. Truncated age-standardized rates per 100,000 for the ages 40-74 were used to summarise recent geographical variations. Standardized rate ratios and 95% confidence intervals for the periods 1986-1990 and 1991-1995 were compared to assess geographical variations in risk. To investigate changes in the magnitude of most recent trends, regression models fitted to the latest available 10-year period (1988-1997) were compared with trends in the previous decade. Fitted rates in younger (40-64) and older adults (65-74) in the most recent period were also compared. RESULTS: There was a great deal of geographical variation in the risk of @entity2615 , annual rates ranging from around 8 per 100,000 in Scotland, England and The Netherlands, to lower than 1 per 100,000 in Spain (0.96), Estonia (0.85), Poland (0.85) and Yugoslavia, Vojvodina (0.56) among @entity1 . The rank of the rates for @entity1 was similar to that observed for @entity1 , although rates were considerably lower. Between 1978 and 1987, rates in @entity1 significantly increased in all countries (excepting Denmark). In the following 10 years, there was a deceleration in trend, and a significant increase was detectable only in England and France. In addition, the magnitude of recent trends in younger @entity1 was generally lower than those estimated for older @entity1 , in both national and regional cancer registry settings. CONCLUSIONS: While @entity2615 incidence rates are still rising in Europe, a deceleration has started in some countries. A decrease may begin in the next few years in certain European populations considering the deceleration of observed trends in @entity2615 and @entity1355 exposure, as well as the recent ban on its use.

title: XXXX incidence in Europe: evidence of some deceleration in the increasing trends.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity2615 :: ('MESH:D008654', 'Disease') :: ['pleural mesothelioma', 'mesothelioma']

answer: @entity2615 :: (MESH:D008654,Disease) :: ['Pleural mesothelioma']


abstract: PURPOSE: To report the ocular manifestations of acute serologically confirmed @entity19 typhus. METHODS: A retrospective analysis of the clinical history, photography and fluorescein angiography of two @entity1 with acute @entity19 typhus with ocular involvement was conducted. RESULTS: A 38 year old male and a 49 year old female were included in the study. Both complained of @entity221 , @entity10 , @entity1910 , night sweats and @entity358 . They had noted the recent onset of diminished visual acuity and floaters. Examination of the posterior pole revealed mild optic nerve head @entity4 (in one @entity1 ), @entity548 and small localized areas of retinal whitening. The history confirmed that both @entity1 had been exposed to fleas and the serologic testing was positive for @entity13167 . The systemic and ocular findings resolved after the use of systemic antibiotics. CONCLUSION: @entity66 such as @entity19 typhus should be included in the differential diagnosis of otherwise healthy individuals who present with an acute systemic @entity221 and @entity2479 or @entity2479 . SUMMARY STATEMENT: The clinical features of two @entity1 with serologically proven acute @entity19 typhus with ocular involvement are presented. Both @entity1 presented with a retinal whitening that resolved after treatment.

title: Retinal manifestations of acute XXXX typhus.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Rickettsial diseases']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['intraretinal hemorrhages']

entities_list: @entity13167 :: ('785', 'Species') :: ['Rickettsia typhi']

entities_list: @entity2479 :: ('MESH:D012173', 'Disease') :: ['retinitis', 'neuroretinitis']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary symptoms']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['febrile illness', 'fever']

answer: @entity19 :: (10090,Species) :: ['murine']


abstract: The use of natural antioxidants and @entity3088 in nutritional and pharmaceutical applications is increasing. Because some phytochemicals such as @entity670 , found in soy products, have estrogenic activity, we investigated the estrogenic potential of a natural antioxidant mixture ( @entity1846 ) isolated from @entity2772 leaves, using an in vivo uterotrophic bioassay and an in vitro transcriptional activation assay for the @entity172 receptor (ER). Outbred female @entity2659 @entity19 (17 d old) were given subcutaneous injections of @entity53 or @entity670 [500 and 500,000 microg /(kg x d), respectively] as positive controls or @entity1846 [1000 to 1,000,000 microg/(kg x d)] for 3 d. Uterine wet weight/body weight ratios were determined. Both @entity53 and @entity670 significantly increased uterine wet weight ratios compared with untreated controls, but @entity1846 did not. Histological examination of the uterus showed that @entity53 and @entity670 increased epithelial cell height, number and gland development, but @entity1846 did not. Estrogenic activity of @entity1846 was investigated in vitro using the ER transcriptional activation assay. BG1Luc4E2 cells expressing ER were stably transfected with a luciferase reporter gene responsive to @entity172 . @entity53 dose dependently increased luciferase activity; @entity1846 had no effect. When @entity1846 was tested for antiestrogenic activity, it did not lessen the effects of @entity53 . These data suggest that @entity1846 does not have estrogenic or antiestrogenic activity. Thus, an antioxidant mixture has been identified that does not have potentially adverse estrogenic activity.

title: A natural antioxidant mixture from XXXX does not have estrogenic or antiestrogenic activity in immature @entity2659 @entity19 .

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen', 'estrogens']

entities_list: @entity670 :: ('MESH:D019833', 'Chemical') :: ['genistein']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['17beta-estradiol']

entities_list: @entity3088 :: ('MESH:D005419', 'Chemical') :: ['flavonoids']

answer: @entity2772 :: (3562,Species) :: ['spinach']


abstract: The use of natural antioxidants and @entity3088 in nutritional and pharmaceutical applications is increasing. Because some phytochemicals such as @entity670 , found in soy products, have estrogenic activity, we investigated the estrogenic potential of a natural antioxidant mixture ( @entity1846 ) isolated from @entity2772 leaves, using an in vivo uterotrophic bioassay and an in vitro transcriptional activation assay for the @entity172 receptor (ER). Outbred female @entity2659 @entity19 (17 d old) were given subcutaneous injections of @entity53 or @entity670 [500 and 500,000 microg /(kg x d), respectively] as positive controls or @entity1846 [1000 to 1,000,000 microg/(kg x d)] for 3 d. Uterine wet weight/body weight ratios were determined. Both @entity53 and @entity670 significantly increased uterine wet weight ratios compared with untreated controls, but @entity1846 did not. Histological examination of the uterus showed that @entity53 and @entity670 increased epithelial cell height, number and gland development, but @entity1846 did not. Estrogenic activity of @entity1846 was investigated in vitro using the ER transcriptional activation assay. BG1Luc4E2 cells expressing ER were stably transfected with a luciferase reporter gene responsive to @entity172 . @entity53 dose dependently increased luciferase activity; @entity1846 had no effect. When @entity1846 was tested for antiestrogenic activity, it did not lessen the effects of @entity53 . These data suggest that @entity1846 does not have estrogenic or antiestrogenic activity. Thus, an antioxidant mixture has been identified that does not have potentially adverse estrogenic activity.

title: A natural antioxidant mixture from @entity2772 does not have estrogenic or antiestrogenic activity in immature XXXX @entity19 .

answer: @entity2659 :: (111334(Tax:10090),Gene) :: ['CD-1']


abstract: The use of natural antioxidants and @entity3088 in nutritional and pharmaceutical applications is increasing. Because some phytochemicals such as @entity670 , found in soy products, have estrogenic activity, we investigated the estrogenic potential of a natural antioxidant mixture ( @entity1846 ) isolated from @entity2772 leaves, using an in vivo uterotrophic bioassay and an in vitro transcriptional activation assay for the @entity172 receptor (ER). Outbred female @entity2659 @entity19 (17 d old) were given subcutaneous injections of @entity53 or @entity670 [500 and 500,000 microg /(kg x d), respectively] as positive controls or @entity1846 [1000 to 1,000,000 microg/(kg x d)] for 3 d. Uterine wet weight/body weight ratios were determined. Both @entity53 and @entity670 significantly increased uterine wet weight ratios compared with untreated controls, but @entity1846 did not. Histological examination of the uterus showed that @entity53 and @entity670 increased epithelial cell height, number and gland development, but @entity1846 did not. Estrogenic activity of @entity1846 was investigated in vitro using the ER transcriptional activation assay. BG1Luc4E2 cells expressing ER were stably transfected with a luciferase reporter gene responsive to @entity172 . @entity53 dose dependently increased luciferase activity; @entity1846 had no effect. When @entity1846 was tested for antiestrogenic activity, it did not lessen the effects of @entity53 . These data suggest that @entity1846 does not have estrogenic or antiestrogenic activity. Thus, an antioxidant mixture has been identified that does not have potentially adverse estrogenic activity.

title: A natural antioxidant mixture from @entity2772 does not have estrogenic or antiestrogenic activity in immature @entity2659 XXXX .

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: In individuals with @entity1120 , childhood manifestations are usually predictive of a more severe phenotype. Although @entity1 with @entity1120 are at risk of irreversible disease complications, early intervention with an optimal dose of enzyme therapy can prevent the development of complications and ensure adequate, potentially normal, development through childhood and adolescence. Very few, if any, @entity1 diagnosed by signs and symptoms should go untreated. Evidence suggests that disease severity, disease progression and treatment response in different organs where glucocerebroside accumulates are often non-uniform in affected individuals. Therefore, serial monitoring of the affected compartments is important. This should include a thorough physical examination at 6- to 12-monthly intervals. Neurological assessment should be performed to rule out neurological involvement and should be undertaken periodically thereafter in @entity1 who are considered to have risk factors for developing @entity66 . Haematological and biochemical markers, such as haemoglobin, platelet counts and chitotriosidase levels, should be assessed every 3 months initially, but when clinical goals have been met through treatment with enzyme therapy, the frequency can be reduced to every 12 to 24 months. Careful monitoring of @entity79 is vitally important, as the resulting sequelae are associated with the greatest level of morbidity. By combining various imaging modalities, the skeletal complications of @entity1120 can be effectively monitored so that irreversible skeletal pathology is avoided and @entity158 due to bone involvement is diminished or eliminated. Monitoring must include regular psychosocial, functional status and quality-of-life evaluation, as well as consistent assessment of therapeutic goal attainment and necessary dosage adjustments based on the @entity1 's progress. CONCLUSION: Through comprehensive and serial monitoring, ultimately, a therapeutic dose of enzyme therapy that achieves sustained benefits can be found for each @entity1 with non-neuronpathic @entity1120 .

title: Paediatric XXXX : recommendations for treatment and monitoring.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patient', 'child']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['neuronopathic disease']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone disease']

entities_list: @entity1120 :: ('MESH:D005776', 'Disease') :: ['Gaucher disease', 'non-neuronopathic Gaucher disease']

answer: @entity1120 :: (MESH:D005776,Disease) :: ['non-neuronopathic Gaucher disease']


abstract: BACKGROUND: As a complication of chemotherapy/corticosteroids for the treatment of @entity981 ( @entity981 ) and other @entity5 during childhood, avascular @entity2530 appears in up to 30 % of the @entity1 . Weight-bearing joints are involved in over 90 % of the cases. Total joint replacement is often necessary to restore function. Yet, endoprostheses in young @entity1 again bare the risk of later complications and the need for several revision surgeries. In this report, joint preserving surgical strategies will be discussed. @entity1 : Three hips and eleven knee joints in 8 @entity1 (4 male, 4 female) were operated on for symptomatic ON and/or @entity4713 ( @entity4713 ) after chemotherapy. Four of the @entity1 underwent surgery in more than one joint. The average age at the time of surgery was 18 years (range 14 - 26). The procedures included retrograde drilling (core decompression), bone grafting, implantation of collagen sponges with autologous bone marrow aspirate, osteochondral autograft transplantation and transplantation of periosteal flaps. Two hip joints underwent total joint replacement. Average follow up was 25 months. RESULTS: After an average follow up of 2 years, all @entity1 were satisfied with the functional results after the last follow up with @entity158 free walking for a minimum of 60 minutes. No night @entity158 was reported. One @entity1 complained about intermittent periods of dysaesthesia around the bone harvest area at the iliac crest. CONCLUSIONS: The aim of surgery for ON and @entity4713 after chemotherapy should be the reduction of @entity158 and preservation of the joint to bypass the risks of joint replacement in young @entity1 , although total joint replacement may become indicated in endstage degeneration of the involved joint.

title: Joint preserving surgery for @entity2530 and XXXX after chemotherapy in childhood.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL', 'acute lymphoblastic leukemia']

entities_list: @entity4713 :: ('MESH:D010007', 'Disease') :: ['osteochondral defects', 'OCD']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

entities_list: @entity2530 :: ('MESH:D010020', 'Disease') :: ['osteonecrosis']

answer: @entity4713 :: (MESH:D010007,Disease) :: ['osteochondral defects']


abstract: BACKGROUND: As a complication of chemotherapy/corticosteroids for the treatment of @entity981 ( @entity981 ) and other @entity5 during childhood, avascular @entity2530 appears in up to 30 % of the @entity1 . Weight-bearing joints are involved in over 90 % of the cases. Total joint replacement is often necessary to restore function. Yet, endoprostheses in young @entity1 again bare the risk of later complications and the need for several revision surgeries. In this report, joint preserving surgical strategies will be discussed. @entity1 : Three hips and eleven knee joints in 8 @entity1 (4 male, 4 female) were operated on for symptomatic ON and/or @entity4713 ( @entity4713 ) after chemotherapy. Four of the @entity1 underwent surgery in more than one joint. The average age at the time of surgery was 18 years (range 14 - 26). The procedures included retrograde drilling (core decompression), bone grafting, implantation of collagen sponges with autologous bone marrow aspirate, osteochondral autograft transplantation and transplantation of periosteal flaps. Two hip joints underwent total joint replacement. Average follow up was 25 months. RESULTS: After an average follow up of 2 years, all @entity1 were satisfied with the functional results after the last follow up with @entity158 free walking for a minimum of 60 minutes. No night @entity158 was reported. One @entity1 complained about intermittent periods of dysaesthesia around the bone harvest area at the iliac crest. CONCLUSIONS: The aim of surgery for ON and @entity4713 after chemotherapy should be the reduction of @entity158 and preservation of the joint to bypass the risks of joint replacement in young @entity1 , although total joint replacement may become indicated in endstage degeneration of the involved joint.

title: Joint preserving surgery for XXXX and @entity4713 after chemotherapy in childhood.

answer: @entity2530 :: (MESH:D010020,Disease) :: ['osteonecrosis']


abstract: A significant proportion of @entity1 with @entity162 are @entity2147 . It is not clear if this affects response to treatment because few studies have systematically examined treatment effects on sleep in @entity1 with @entity162 . Reported herein are the results of what we believe to be the first study of the effects of the @entity1154 oxidase inhibitor @entity5832 (average dose=37 mg/day) on the sleep of @entity1 with @entity162 .Twenty-three @entity1 with anergic @entity162 completed sleep studies before and after pharmacotherapy. Changes in polysomnographic variables were examined using paired t tests. The @entity1 experienced a 40% reduction in @entity1319 ( @entity1319 ) sleep time, as well as significant decreases in @entity1319 percentage, @entity1319 activity, number of @entity1319 periods, and @entity1319 intensity. @entity1319 latency was prolonged by nearly 3-fold. The decrease in @entity1319 sleep was accompanied by a modest (8%) reduction in total sleep time and increased "light" sleep. There was no change in sleep continuity indices or slow wave sleep. Correlational analyses suggested that antidepressant response was only weakly associated with changes in @entity1319 sleep. These findings indicate that @entity5832 's effects on @entity1319 sleep greatly surpass effects on sleep architecture or sleep maintenance. Moreover, effective treatment of @entity162 did not "normalize" the @entity2147 associated with @entity162 .

title: Effects of @entity5832 on the sleep of @entity1 with anergic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar depression', 'bipolar disorder']

entities_list: @entity2147 :: ('MESH:D006970', 'Disease') :: ['hypersomnolence', 'hypersomnolent']

entities_list: @entity5832 :: ('MESH:D014191', 'Chemical') :: ['tranylcypromine']

entities_list: @entity1154 :: ('CHEBI:25375', 'Chemical') :: ['monoamine']

entities_list: @entity1319 :: ('MESH:D015835', 'Disease') :: ['REM', 'rapid eye movement']

answer: @entity162 :: (MESH:D001714,Disease) :: ['bipolar depression']


abstract: A significant proportion of @entity1 with @entity162 are @entity2147 . It is not clear if this affects response to treatment because few studies have systematically examined treatment effects on sleep in @entity1 with @entity162 . Reported herein are the results of what we believe to be the first study of the effects of the @entity1154 oxidase inhibitor @entity5832 (average dose=37 mg/day) on the sleep of @entity1 with @entity162 .Twenty-three @entity1 with anergic @entity162 completed sleep studies before and after pharmacotherapy. Changes in polysomnographic variables were examined using paired t tests. The @entity1 experienced a 40% reduction in @entity1319 ( @entity1319 ) sleep time, as well as significant decreases in @entity1319 percentage, @entity1319 activity, number of @entity1319 periods, and @entity1319 intensity. @entity1319 latency was prolonged by nearly 3-fold. The decrease in @entity1319 sleep was accompanied by a modest (8%) reduction in total sleep time and increased "light" sleep. There was no change in sleep continuity indices or slow wave sleep. Correlational analyses suggested that antidepressant response was only weakly associated with changes in @entity1319 sleep. These findings indicate that @entity5832 's effects on @entity1319 sleep greatly surpass effects on sleep architecture or sleep maintenance. Moreover, effective treatment of @entity162 did not "normalize" the @entity2147 associated with @entity162 .

title: Effects of XXXX on the sleep of @entity1 with anergic @entity162 .

answer: @entity5832 :: (MESH:D014191,Chemical) :: ['tranylcypromine']


abstract: A significant proportion of @entity1 with @entity162 are @entity2147 . It is not clear if this affects response to treatment because few studies have systematically examined treatment effects on sleep in @entity1 with @entity162 . Reported herein are the results of what we believe to be the first study of the effects of the @entity1154 oxidase inhibitor @entity5832 (average dose=37 mg/day) on the sleep of @entity1 with @entity162 .Twenty-three @entity1 with anergic @entity162 completed sleep studies before and after pharmacotherapy. Changes in polysomnographic variables were examined using paired t tests. The @entity1 experienced a 40% reduction in @entity1319 ( @entity1319 ) sleep time, as well as significant decreases in @entity1319 percentage, @entity1319 activity, number of @entity1319 periods, and @entity1319 intensity. @entity1319 latency was prolonged by nearly 3-fold. The decrease in @entity1319 sleep was accompanied by a modest (8%) reduction in total sleep time and increased "light" sleep. There was no change in sleep continuity indices or slow wave sleep. Correlational analyses suggested that antidepressant response was only weakly associated with changes in @entity1319 sleep. These findings indicate that @entity5832 's effects on @entity1319 sleep greatly surpass effects on sleep architecture or sleep maintenance. Moreover, effective treatment of @entity162 did not "normalize" the @entity2147 associated with @entity162 .

title: Effects of @entity5832 on the sleep of XXXX with anergic @entity162 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: Our aim was to determine the outcome of arthroscopic-assisted reduction with bilateral buttress plate fixation for the treatment of @entity6044 . TYPE OF STUDY: Case series. METHODS: 18 consecutive @entity1 (12 @entity1 , 6 @entity1 ) with @entity174 were enrolled in this prospective study. All @entity1 underwent arthroscopic-assisted bilateral buttress plate fixation of @entity6044 . The average age at operation was 35 years (range, 23 to 45 years). The follow-up period ranged from 39 to 69 months, with an average of 48 months. Using the Schatzker classification, there were 11 type V and 7 type VI @entity174 . The clinical and radiological outcomes were determined according to Rasmussen's system. RESULTS: All of the 18 @entity174 united. Overall, 4 (22%) @entity1 were rated as excellent, 12 (67%) good, and 2 (11%) fair. Secondary @entity571 appeared in 3 injured knees (16.7%). One @entity1 had a wound dehiscence (3 cm long) of the medial incision. @entity308 was noted in 3 @entity1 without functional instability. Two @entity1 had valgus alignment between 10 degrees and 15 degrees. Two @entity1 had the paresthesia over the lateral @entity291 . There were no complications directly associated with arthroscopy in any of the 18 @entity1 . No @entity1150 , @entity281 , or knee stiffness was found at final follow-up. CONCLUSIONS: Arthroscopic-assisted reduction with bilateral buttress plate fixation for @entity174 allows accurate @entity174 reduction, diagnosis, and treatment of associated @entity75 , and less dissection than open reduction internal fixation.

title: Arthroscopic-assisted reduction with bilateral buttress plate XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Condylar joint surface depression']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['osteoarthritis']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture', 'complex tibial plateau fractures']

entities_list: @entity6044 :: ('MESH:D005596', 'Disease') :: ['closed complex tibial plateau fractures']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['intra-articular lesions']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity174 :: (MESH:D050723,Disease) :: ['fixation of complex tibial plateau fractures']


abstract: The incidence of @entity0 increases with advancing age. In view of the progressive aging of the population, this problem will tend to become more and more frequent. At present, @entity1 of advanced age are often "undertreated" owing to the mistaken prejudice that older @entity1 are unable to withstand standard multimodal therapy for this disease. In fact, there is no scientific evidence to that effect. Treatment choices should therefore be largely comparable to those adopted in younger @entity1 . Even chemotherapy, which encounters the strongest resistance, by @entity1 but also by doctors, should be administered when indicated. A number of studies have demonstrated that the toxic and side effects observed in elderly @entity1 are comparable to those observed in younger age groups. In practice, particular attention needs to be paid when administering cytostatic treatment to @entity1 over 80 years of age. Very conservative treatment ( @entity440 plus radiotherapy) may be reserved only to particularly frail elderly @entity1 . In conclusion, the therapeutic choice should depend more on assessment of the biological age, life expectancy and @entity1 's expectations than on the anagraphic age.

title: [ XXXX in advanced age].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast carcinoma']

answer: @entity0 :: (MESH:D001943,Disease) :: ['Breast cancer']


abstract: The aim of the present study was to investigate local vascular and sensory changes and their correlation in order to obtain a better understanding of the mechanisms of @entity1931 , @entity1931 and vascular changes following tissue @entity32 induced by repetitive application of @entity2951 cream. This type of application was utilized as a controlled model of @entity32 which was altered in intensity due to its repetitive applicability. Ten healthy volunteers participated in two experiments separated by at least five days. Each experiment consisted of a baseline session followed by five additional sessions. Before these sessions either 1.5 g @entity2951 (1%) or placebo cream was applied to the volar site of the forearm for 15 min. The areas of stroking @entity1931 and pin-prick @entity1931 were mapped and the intensity of spontaneous @entity158 (VAS) was assessed after each application of the cream. In addition, the visible flare, temperature (IR-Thermography), and blood- flow (Laser-Doppler) were measured. The first application of @entity2951 was perceived as painful; it induced both @entity1931 and @entity1931 . Compared to placebo, the first application of @entity2951 cream also resulted in an increased blood-flow, elevated temperature and visible flare. The highest values of these sensory and vascular parameters were reached after the third application. A direct correlation between visible flare, secondary @entity1931 and @entity1931 following repetitive application of @entity2951 indicates that both common central and peripheral mechanisms were involved in these changes.

title: Correlation between local vascular and sensory changes following tissue @entity32 induced by repetitive application of topical XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1931 :: ('MESH:D006930', 'Disease') :: ['mechanical hyperalgesia', 'hyperalgesia', 'allodynia', 'secondary hyperalgesia']

entities_list: @entity2951 :: ('MESH:D002211', 'Chemical') :: ['capsaicin']

answer: @entity2951 :: (MESH:D002211,Chemical) :: ['capsaicin']


abstract: The aim of the present study was to investigate local vascular and sensory changes and their correlation in order to obtain a better understanding of the mechanisms of @entity1931 , @entity1931 and vascular changes following tissue @entity32 induced by repetitive application of @entity2951 cream. This type of application was utilized as a controlled model of @entity32 which was altered in intensity due to its repetitive applicability. Ten healthy volunteers participated in two experiments separated by at least five days. Each experiment consisted of a baseline session followed by five additional sessions. Before these sessions either 1.5 g @entity2951 (1%) or placebo cream was applied to the volar site of the forearm for 15 min. The areas of stroking @entity1931 and pin-prick @entity1931 were mapped and the intensity of spontaneous @entity158 (VAS) was assessed after each application of the cream. In addition, the visible flare, temperature (IR-Thermography), and blood- flow (Laser-Doppler) were measured. The first application of @entity2951 was perceived as painful; it induced both @entity1931 and @entity1931 . Compared to placebo, the first application of @entity2951 cream also resulted in an increased blood-flow, elevated temperature and visible flare. The highest values of these sensory and vascular parameters were reached after the third application. A direct correlation between visible flare, secondary @entity1931 and @entity1931 following repetitive application of @entity2951 indicates that both common central and peripheral mechanisms were involved in these changes.

title: Correlation between local vascular and sensory changes following tissue XXXX induced by repetitive application of topical @entity2951 .

answer: @entity32 :: (MESH:D007249,Disease) :: ['inflammation']


abstract: BACKGROUND: Endotoxin is a major stimulus for triggering the host response in @entity295 . The pathophysiology of @entity295 involves activation of the vascular endothelium and leukocytes, resulting in the release of various mediators, e.g. cytokines, @entity842 (NO), endothelin (ET-1) and complement factors. We evaluated the blood levels of complement activation, ET-1 and @entity7766 (NPY) in parallel with the haemodynamic and @entity26 transport response during @entity1 experimental @entity5694 . METHODS: Eleven healthy @entity1 had venous, arterial and pulmonary arterial catheters placed for continuous haemodynamic measuring. After 30 min rest endotoxin ( @entity526 4 ng kg(-1), Lot G1) was intravenously administered. Blood samples from pulmonary and arterial catheters were collected hourly over 4 h. RESULTS: Body temperature augmented significantly from baseline values (36.7 +/- 0.7 degrees C, mean +/- SEM) with a maximum after 3.5 h (39.1 +/- 0.3 degrees C, P < 0.001). Cardiac output increased by 100%, systemic vascular resistance decreased by 50%, the @entity26 consumption and the tissue @entity26 transport increased. Activation of the complement system was indicated by an increase in SC5b-9. @entity2232 -like immunoreactivity (ET-1- @entity3162 ) increased over time in arterial blood. NPY-like immunoreactivity (NPY- @entity3162 ) did not change over time. CONCLUSION: A dose of endotoxin associated with reproducible systemic vasodilation and fever in healthy subjects causes complement activation and increased systemic levels of ET-1- @entity3162 , illustrating that the model is a useful tool for inducing moderate systemic @entity32 where several mediator systems are activated.

title: Complement activation, XXXX and @entity7766 in relation to the cardiovascular response to endotoxin-induced systemic @entity32 in healthy volunteers.

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis', 'septicaemia']

entities_list: @entity5694 :: ('MESH:D019446', 'Disease') :: ['endotoxemia']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

answer: @entity2232 :: (1906,Gene) :: ['endothelin-1']


abstract: BACKGROUND: Endotoxin is a major stimulus for triggering the host response in @entity295 . The pathophysiology of @entity295 involves activation of the vascular endothelium and leukocytes, resulting in the release of various mediators, e.g. cytokines, @entity842 (NO), endothelin (ET-1) and complement factors. We evaluated the blood levels of complement activation, ET-1 and @entity7766 (NPY) in parallel with the haemodynamic and @entity26 transport response during @entity1 experimental @entity5694 . METHODS: Eleven healthy @entity1 had venous, arterial and pulmonary arterial catheters placed for continuous haemodynamic measuring. After 30 min rest endotoxin ( @entity526 4 ng kg(-1), Lot G1) was intravenously administered. Blood samples from pulmonary and arterial catheters were collected hourly over 4 h. RESULTS: Body temperature augmented significantly from baseline values (36.7 +/- 0.7 degrees C, mean +/- SEM) with a maximum after 3.5 h (39.1 +/- 0.3 degrees C, P < 0.001). Cardiac output increased by 100%, systemic vascular resistance decreased by 50%, the @entity26 consumption and the tissue @entity26 transport increased. Activation of the complement system was indicated by an increase in SC5b-9. @entity2232 -like immunoreactivity (ET-1- @entity3162 ) increased over time in arterial blood. NPY-like immunoreactivity (NPY- @entity3162 ) did not change over time. CONCLUSION: A dose of endotoxin associated with reproducible systemic vasodilation and fever in healthy subjects causes complement activation and increased systemic levels of ET-1- @entity3162 , illustrating that the model is a useful tool for inducing moderate systemic @entity32 where several mediator systems are activated.

title: Complement activation, @entity2232 and XXXX in relation to the cardiovascular response to endotoxin-induced systemic @entity32 in healthy volunteers.

answer: @entity7766 :: (4852,Gene) :: ['neuropeptide Y']


abstract: BACKGROUND: Endotoxin is a major stimulus for triggering the host response in @entity295 . The pathophysiology of @entity295 involves activation of the vascular endothelium and leukocytes, resulting in the release of various mediators, e.g. cytokines, @entity842 (NO), endothelin (ET-1) and complement factors. We evaluated the blood levels of complement activation, ET-1 and @entity7766 (NPY) in parallel with the haemodynamic and @entity26 transport response during @entity1 experimental @entity5694 . METHODS: Eleven healthy @entity1 had venous, arterial and pulmonary arterial catheters placed for continuous haemodynamic measuring. After 30 min rest endotoxin ( @entity526 4 ng kg(-1), Lot G1) was intravenously administered. Blood samples from pulmonary and arterial catheters were collected hourly over 4 h. RESULTS: Body temperature augmented significantly from baseline values (36.7 +/- 0.7 degrees C, mean +/- SEM) with a maximum after 3.5 h (39.1 +/- 0.3 degrees C, P < 0.001). Cardiac output increased by 100%, systemic vascular resistance decreased by 50%, the @entity26 consumption and the tissue @entity26 transport increased. Activation of the complement system was indicated by an increase in SC5b-9. @entity2232 -like immunoreactivity (ET-1- @entity3162 ) increased over time in arterial blood. NPY-like immunoreactivity (NPY- @entity3162 ) did not change over time. CONCLUSION: A dose of endotoxin associated with reproducible systemic vasodilation and fever in healthy subjects causes complement activation and increased systemic levels of ET-1- @entity3162 , illustrating that the model is a useful tool for inducing moderate systemic @entity32 where several mediator systems are activated.

title: Complement activation, @entity2232 and @entity7766 in relation to the cardiovascular response to endotoxin-induced systemic XXXX in healthy volunteers.

answer: @entity32 :: (MESH:D007249,Disease) :: ['inflammation']


abstract: VDD pacing provides the physiological benefits of atrioventricular synchronous pacing with the convenience of a single lead system, but is hampered by uncertainty regarding long-term atrial sensing and potential development of @entity1817 . To examine the long-term reliability and complication rates of VDD pacing, we compared the outcome of 112 consecutive @entity1 (age 70 +/- 13 years, 59% male) with symptomatic @entity713 who received a single pass bipolar VDD system to 80 @entity1 (age 63 +/- 16 years, 70% male) who received @entity3603 pacing for the same indication. All @entity1 were judged to have intact sinus node function based on submitted ECGs and monitoring results at the time of implant. Implant time was reduced in VDD @entity1 compared to @entity3603 @entity1 (63 +/- 20 vs 97 +/- 36 minutes, P < 0.0001). Implant complications occurred in 5 (6%) @entity3603 @entity1 compared to 3 (3%) VDD @entity1 (P = 0.15). The implant P wave was lower with VDD pacing compared to @entity3603 @entity1 (2.91 +/- 1.48 vs 4.0 +/- 1.7 mV, P < 0.0001), but remained stable during long-term follow-up in both groups. During 17.7 +/- 10.0 months of follow-up in the VDD group, only 2 VDD @entity1 were reprogrammed to VVIR mode, compared to 3 @entity3603 @entity1 . Physiological atrioventricular activation was maintained in 94%-99% of beats throughout the follow-up period in the VDD group. VDD pacing is an excellent strategy for treatment of @entity1 with symptomatic @entity713 . The lower cost, high reliability, and abbreviated implantation time suggest that VDD pacing is a viable alternative to @entity3603 pacing in @entity1 with high-degree @entity713 and normal sinus node function.

title: Optimal pacing for symptomatic @entity713 : a comparison of VDD and XXXX pacing.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1817 :: ('MESH:D012804', 'Disease') :: ['sinus node disease']

answer: @entity3603 :: (MESH:C562924,Disease) :: ['DDD']


abstract: VDD pacing provides the physiological benefits of atrioventricular synchronous pacing with the convenience of a single lead system, but is hampered by uncertainty regarding long-term atrial sensing and potential development of @entity1817 . To examine the long-term reliability and complication rates of VDD pacing, we compared the outcome of 112 consecutive @entity1 (age 70 +/- 13 years, 59% male) with symptomatic @entity713 who received a single pass bipolar VDD system to 80 @entity1 (age 63 +/- 16 years, 70% male) who received @entity3603 pacing for the same indication. All @entity1 were judged to have intact sinus node function based on submitted ECGs and monitoring results at the time of implant. Implant time was reduced in VDD @entity1 compared to @entity3603 @entity1 (63 +/- 20 vs 97 +/- 36 minutes, P < 0.0001). Implant complications occurred in 5 (6%) @entity3603 @entity1 compared to 3 (3%) VDD @entity1 (P = 0.15). The implant P wave was lower with VDD pacing compared to @entity3603 @entity1 (2.91 +/- 1.48 vs 4.0 +/- 1.7 mV, P < 0.0001), but remained stable during long-term follow-up in both groups. During 17.7 +/- 10.0 months of follow-up in the VDD group, only 2 VDD @entity1 were reprogrammed to VVIR mode, compared to 3 @entity3603 @entity1 . Physiological atrioventricular activation was maintained in 94%-99% of beats throughout the follow-up period in the VDD group. VDD pacing is an excellent strategy for treatment of @entity1 with symptomatic @entity713 . The lower cost, high reliability, and abbreviated implantation time suggest that VDD pacing is a viable alternative to @entity3603 pacing in @entity1 with high-degree @entity713 and normal sinus node function.

title: Optimal pacing for symptomatic XXXX : a comparison of VDD and @entity3603 pacing.

answer: @entity713 :: (MESH:D054537,Disease) :: ['AV block']


abstract: We examined whether the detection of dysgranulopoiesis in blood or bone marrow would predict @entity1860 ( @entity1860 ) in transformation in 31 cases that fulfilled World Health Organization criteria for disease transformation, including 14 in accelerated phase (AP), 10 in @entity9638 ( @entity9638 ), and 7 in @entity706 ( @entity706 ). Dysgranulopoiesis was detected in 7 cases, 6 in AP and 1 in @entity9638 , but not in @entity706 or chronic phase cases. In 3 AP cases, dysgranulopoiesis was identified 2 to 5 months before the morphologic diagnosis of transformation. Two AP cases showed no dysgranulopoiesis in previous blood or marrow smears. For 2 cases (1 AP and 1 @entity9638 ), no previous blood or marrow specimens were available. Cytogenetic information was available for 6 of 7 cases with and 22 of 24 cases without dysgranulopoiesis. All cases with dysgranulopoiesis had secondary chromosome abnormalities in addition to t(9;22). In 5 (83%) of 6 cases with dysgranulopoiesis, the secondary chromosome abnormalities included @entity854 . In contrast, none of the 22 cases of @entity1860 in AP or BC but without dysgranulopoiesis showed 17p abnormalities (P = .001). Our findings demonstrated that dysgranulopoiesis was associated strongly with chromosome 17p abnormalities and may indicate the onset of or impending disease transformation.

title: Diagnostic significance of detecting dysgranulopoiesis in XXXX .

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['abnormalities of 17p']

entities_list: @entity9638 :: ('MESH:D001752', 'Disease') :: ['myeloid blast crisis', 'MBC']

entities_list: @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['LBC', 'lymphoid blast crisis']

answer: @entity1860 :: (MESH:D015464,Disease) :: ['chronic myeloid leukemia']


abstract: PURPOSE: This study aimed to evaluate the prognostic significance of the modified Glasgow Prognostic Score (mGPS) in @entity1 with @entity1149 ( @entity1149 ) who received stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Data from 165 @entity1 who underwent SBRT for stage I @entity1149 with histologic confirmation from January 1999 to September 2010 were collected retrospectively. Factors, including age, performance status, histology, Charlson comorbidity index, mGPS, and recursive partitioning analysis (RPA) class based on sex and T stage, were evaluated with regard to @entity1349 ( @entity1349 ) using the Cox proportional hazards model. The impact of the mGPS on cause of @entity204 and failure patterns was also analyzed. RESULTS: The 3-year @entity1349 was 57.9%, with a median follow-up time of 3.5 years. A higher mGPS correlated significantly with poor @entity1349 (P<.001). The 3-year @entity1349 of lower mGPS @entity1 was 66.4%, whereas that of higher mGPS @entity1 was 44.5%. On multivariate analysis, mGPS and RPA class were significant factors for @entity1349 . A higher mGPS correlated significantly with @entity2 @entity204 (P=.019) and distant @entity3 (P=.013). CONCLUSIONS: The mGPS was a significant predictor of clinical outcomes for SBRT in @entity1149 @entity1 .

title: Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage XXXX .

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['Non-Small Cell Lung Cancer']


abstract: Recognition of Ras by its downstream target @entity8496 is mediated by a Ras-recognition region in the Ras-binding domain (RBD) of @entity8496 . Residues 78-89 in this region occupy two different conformations in the ensemble of NMR solution structures of the RBD: a fully alpha-helical one, and one where 87-90 form a type IV beta-turn. Molecular dynamics simulations of the RBD in solution were performed to explore the stability of these and other possible conformations of both the wild-type RBD and the @entity70655 mutant, which does not bind Ras. The simulations sample a fully helical conformation for residues 78-89 similar to the NMR helical structures, a conformation where 85-89 form a 3(10)-helical turn, and a conformation where 87-90 form a type I beta-turn, whose free energies are all within 0.3 kcal/mol of each other. NOE patterns and H(alpha) chemical shifts from the simulations are in reasonable agreement with experiment. The NMR turn structure is calculated to be 3 kcal/mol higher than the three above conformations. In a simulation with the same implicit solvent model used in the NMR structure generation, the turn conformation relaxes into the fully helical conformation, illustrating possible structural artifacts introduced by the implicit solvent model. With the @entity8496 @entity70655 mutant, simulations sample a fully helical and a turn conformation, the turn being 0.9 kcal/mol more stable. Thus, the mutation affects the population of RBD conformations, and this is expected to affect Ras binding. For example, if the fully helical conformation of residues 78-89 is required for binding, its free energy increase in @entity70655 will increase the binding free energy by about 0.6 kcal/mol.

title: Conformation of the Ras-binding domain of XXXX studied by molecular dynamics and free energy simulations.

entities_list: @entity70655 :: ('p|SUB|R|89|K', 'ProteinMutation') :: ['R89K']

answer: @entity8496 :: (22882,Gene) :: ['Raf']


abstract: BACKGROUND: Because of the deinstitutionalization of mental health care in Hong Kong that has taken place since the 1980s, many @entity1 with mental health problems are being cared for in the community. The majority of clients have a diagnosis of @entity161 , and many have a long duration of illness and multiple readmissions. There is concern about their quality of life. AIM: To investigate quality of life and related factors in clients with a diagnosis of @entity161 in Hong Kong. DESIGN: A convenience sample was recruited from a @entity146 outpatient department. Structured face-to-face interviews were conducted using the Brief Psychiatric Rating Scale and the Hong Kong Chinese World Health Organization Quality of Life Scale-Brief Version. RESULTS: A total of 172 @entity1 participated in the study. Most of them were single and unemployed. They were least satisfied with their psychological health, financial situation, life enjoyment and sexual activity. @entity1 (n = 91) reported less satisfaction with quality of life than @entity1 (n = 86). Unemployed @entity1 (n = 100) were less satisfied with their quality of life than the employed (n = 76). Higher levels of mental health problems and higher numbers of previous hospitalizations were associated with negative perceptions of quality of life. DISCUSSION: @entity1 with mental health problems had significantly less satisfaction with their quality of life than a sample from the general population in Hong Kong surveyed in a previous study. As well as experiencing distressing mental symptoms, they had many difficulties, such as financial problems, unemployment and lack of opportunities to participate in social activities, that resulted from stigma and discrimination. These had a great impact on their quality of life. STUDY LIMITATIONS: Because of the small sample size and its convenience nature, the findings may not be generalizable to all clients in Hong Kong. A generic instrument was used to measure quality of life, and this may not have been sensitive to certain aspects of mental health clients' lives. CONCLUSION: The findings suggest that there is a need to strengthen social and vocational rehabilitation for @entity1 with mental health problems in Hong Kong. A more holistic and intensive model of care is required to meet their complex needs. A larger and more diverse sample should be used in future research, and a quality of life measure specifically designed for @entity1 with mental health problems should be used.

title: Quality of life of clients with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Women', 'people', 'People', 'men']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

answer: @entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']


abstract: PURPOSE: @entity694 in renal transplant recipients have historically been associated with mortality rates as high as 50 to 100 percent. However, these previous series generally predate the use of @entity205 -based immunosuppressive protocols. METHODS: We retrospectively reviewed all @entity1 who had undergone renal transplant from our institution and who developed complicated @entity4436 . @entity532 was defined as @entity4436 involving free perforation, abscess, phlegmon, or @entity292 . Factors analyzed included the time interval since transplantation, use of @entity205 , living-related vs. cadaveric donor, cause of @entity177 , and presenting signs and symptoms. RESULTS: Between August 1969 and September 1996, 1,211 kidney transplants were performed in 1,137 @entity1 . The first 388 @entity1 (1969-1984) received @entity229 and @entity500 , with @entity205 added to the immunosuppressive regimen for the subsequent 823 recipients (1984-1996). Thirteen (1.1 percent) @entity1 had episodes of complicated @entity4436 , occurring from 25 days to 14 years after transplant; all required surgical therapy. Clinical presentation was highly variable, ranging from asymptomatic @entity516 (2 @entity1 ) to generalized @entity298 . There was one perioperative mortality (7.7 percent). @entity1 with @entity8 as the cause of @entity177 had a significantly higher rate of complicated @entity4436 . Specifically, @entity1 with @entity8 (9 percent of the total transplant population) accounted for 46 percent of the cases of @entity4436 (P < 0.001, Fisher's exact probability test). Neither treatment with @entity205 nor donor source had a significant effect on the rate of diverticular complications (P = 0.36 and P = 0.99, respectively, Fisher's exact probability test). CONCLUSION: @entity532 following renal transplantation is rare, and the clinical presentation may be atypical in the immunosuppressed transplant recipient. @entity1 with @entity8 experience a significantly higher rate of complicated @entity4436 than do other transplant @entity1 and, therefore, warrant aggressive diagnostic evaluation of even vague abdominal symptoms. In addition, pretransplant screening and prophylactic sigmoid resection in this high-risk population deserve consideration and further study.

title: XXXX following renal transplantation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['polycystic kidney disease']

entities_list: @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['Complicated diverticulitis']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity4436 :: ('MESH:D004238', 'Disease') :: ['diverticulitis']

entities_list: @entity516 :: ('MESH:D011027', 'Disease') :: ['pneumoperitoneum']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['Colonic perforations']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['peritonitis']

answer: @entity532 :: (MESH:D003925,Disease) :: ['Complicated diverticulitis']


abstract: The objective of this study was to evaluate the potential survival benefit of debulking macroscopic @entity3018 and other clinical prognostic factors among @entity1 with node-positive @entity1204 . Demographic, operative, pathologic, and follow-up data were abstracted retrospectively for 41 eligible @entity1 with FIGO stage IIIC @entity1204 . Survival curves were generated using the Kaplan-Meier method and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. All @entity1 had positive pelvic lymph nodes and 20 @entity1 (48.8%) had positive para-aortic lymph nodes. Postoperatively, all @entity1 received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 @entity1 received chemotherapy. The median @entity66 ( @entity66 ) time for all @entity1 was 30.6 months (median follow-up 34. 0 months). @entity1 with completely resected macroscopic lymphadenopathy had a significantly longer median @entity66 time (37.5 months), compared to @entity1 left with gross residual @entity66 (8.8 months, P = 0.006). On multivariate analysis, independent predictors of @entity66 were gross residual @entity66 (HR 7.96, 95% CI 2.54-24.97, P < 0. 001), age > or = 65 years (HR 6.22, 95% CI 2.05-18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95% CI 0.07-0.76, P = 0.016). We conclude that in @entity1 with @entity1204 , complete resection of macroscopic @entity66 and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.

title: FIGO @entity1204 : resection of macroscopic XXXX and other determinants of survival.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity3018 :: ('MESH:D009377', 'Disease') :: ['adenopathy']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['DSS', 'disease-specific survival', 'nodal disease']

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial carcinoma', 'endometrial cancer', 'stage IIIC endometrial carcinoma']

answer: @entity66 :: (MESH:D004194,Disease) :: ['nodal disease']


abstract: The objective of this study was to evaluate the potential survival benefit of debulking macroscopic @entity3018 and other clinical prognostic factors among @entity1 with node-positive @entity1204 . Demographic, operative, pathologic, and follow-up data were abstracted retrospectively for 41 eligible @entity1 with FIGO stage IIIC @entity1204 . Survival curves were generated using the Kaplan-Meier method and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. All @entity1 had positive pelvic lymph nodes and 20 @entity1 (48.8%) had positive para-aortic lymph nodes. Postoperatively, all @entity1 received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 @entity1 received chemotherapy. The median @entity66 ( @entity66 ) time for all @entity1 was 30.6 months (median follow-up 34. 0 months). @entity1 with completely resected macroscopic lymphadenopathy had a significantly longer median @entity66 time (37.5 months), compared to @entity1 left with gross residual @entity66 (8.8 months, P = 0.006). On multivariate analysis, independent predictors of @entity66 were gross residual @entity66 (HR 7.96, 95% CI 2.54-24.97, P < 0. 001), age > or = 65 years (HR 6.22, 95% CI 2.05-18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95% CI 0.07-0.76, P = 0.016). We conclude that in @entity1 with @entity1204 , complete resection of macroscopic @entity66 and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.

title: FIGO XXXX : resection of macroscopic @entity66 and other determinants of survival.

answer: @entity1204 :: (MESH:D016889,Disease) :: ['stage IIIC endometrial carcinoma']


abstract: Activated macrophages express inducible isoforms of @entity842 synthase ( @entity13633 ) and cyclooxygenase ( @entity10178 ), and produce excessive amounts of @entity842 (NO) and @entity1421 ( @entity1421 ), which play key roles in the processes of @entity32 and @entity105 . The root of Paeonia lactiflora Pall., and the root cortex of Paeonia suffruticosa Andr., are important Chinese crude drugs used in many traditional prescriptions. @entity22215 ( @entity22216 ) is a major bioactive constituent of both crude drugs. @entity22216 has been shown to possess potent anti-oxidant, anti-mutagenic, anti-proliferative and anti-invasive effects. In this study, we examined the inhibitory effects of @entity22215 ( @entity22216 ) isolated from the root of Paeonia lactiflora Pall. on the @entity10178 and @entity13633 activity in LPS-activated Raw 264.7 cells, @entity16538 in HEL cells. To investigate the structure-activity relationships of gallate and @entity11676 for the inhibition of @entity13633 and @entity10178 activity, we also examined @entity3089 ( @entity3090 ), @entity11676 , and @entity70656 . The results of the present study indicated that @entity22216 , @entity3090 , and @entity70656 treatment except @entity11676 significantly inhibited LPS-induced NO production in LPS-activated macrophages. All of the four compounds significantly inhibited @entity10178 activity in LPS-activated macrophages. Among the four compounds examined, @entity22216 revealed the most potent in both @entity13633 (IC50 approximately 18 microg/mL) and @entity10178 inhibitory activity ( @entity1421 : IC50 approximately 8 microg/mL and @entity15039 : IC50 approximately 12 microg/mL), respectively. Although further studies are needed to elucidate the molecular mechanisms and structure-activity relationship by which @entity22216 exerts its inhibitory actions, our results suggest that @entity22216 might be a candidate for developing anti-inflammatory and @entity5 chemopreventive agents.

title: Inhibition of inducible @entity842 synthase and cyclooxygenase-2 activity by XXXX in murine macrophage cells.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity22215 :: ('MESH:C013185', 'Chemical') :: ['1,2,3,4,6-penta-O-galloyl-beta-D-glucose']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE2', 'prostaglandin E2']

entities_list: @entity3089 :: ('MESH:C045651', 'Chemical') :: ['(-)-epigallocatechin gallate']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis']

entities_list: @entity70656 :: ('MESH:C487425', 'Chemical') :: ['gallacetophenone']

entities_list: @entity11676 :: ('MESH:D005707', 'Chemical') :: ['gallic acid']

answer: @entity22215 :: (MESH:C013185,Chemical) :: ['1,2,3,4,6-penta-O-galloyl-beta-D-glucose']


abstract: Activated macrophages express inducible isoforms of @entity842 synthase ( @entity13633 ) and cyclooxygenase ( @entity10178 ), and produce excessive amounts of @entity842 (NO) and @entity1421 ( @entity1421 ), which play key roles in the processes of @entity32 and @entity105 . The root of Paeonia lactiflora Pall., and the root cortex of Paeonia suffruticosa Andr., are important Chinese crude drugs used in many traditional prescriptions. @entity22215 ( @entity22216 ) is a major bioactive constituent of both crude drugs. @entity22216 has been shown to possess potent anti-oxidant, anti-mutagenic, anti-proliferative and anti-invasive effects. In this study, we examined the inhibitory effects of @entity22215 ( @entity22216 ) isolated from the root of Paeonia lactiflora Pall. on the @entity10178 and @entity13633 activity in LPS-activated Raw 264.7 cells, @entity16538 in HEL cells. To investigate the structure-activity relationships of gallate and @entity11676 for the inhibition of @entity13633 and @entity10178 activity, we also examined @entity3089 ( @entity3090 ), @entity11676 , and @entity70656 . The results of the present study indicated that @entity22216 , @entity3090 , and @entity70656 treatment except @entity11676 significantly inhibited LPS-induced NO production in LPS-activated macrophages. All of the four compounds significantly inhibited @entity10178 activity in LPS-activated macrophages. Among the four compounds examined, @entity22216 revealed the most potent in both @entity13633 (IC50 approximately 18 microg/mL) and @entity10178 inhibitory activity ( @entity1421 : IC50 approximately 8 microg/mL and @entity15039 : IC50 approximately 12 microg/mL), respectively. Although further studies are needed to elucidate the molecular mechanisms and structure-activity relationship by which @entity22216 exerts its inhibitory actions, our results suggest that @entity22216 might be a candidate for developing anti-inflammatory and @entity5 chemopreventive agents.

title: Inhibition of inducible XXXX synthase and cyclooxygenase-2 activity by @entity22215 in murine macrophage cells.

answer: @entity842 :: (MESH:D009569,Chemical) :: ['nitric oxide']


abstract: Problems have been raised by natural genetic diversity of @entity1527 , the causal agent of @entity1526 , and other protozoa in terms of both basic and applied science. @entity1527 manifests a great diversity of medical and biological properties which could be the origin of clinical variability in the disease. We propose possible correlations between genetic distances, or phylogenetic divergence, and histopathological data. To ascertain this aspect, 15 cloned stocks pertaining to three major clones or genotypes (19, 20 and 39) were compared. Sets of 24 @entity19 infected with each stock were studied for histopathological lesions. Brain, heart, lung, liver, spleen, urinary bladder, bone marrow, @entity8 were extracted from each @entity19 . Qualitative and quantitative differences showed at histopathological examination. An important encephalic softening was found in brains of most @entity19 infected by genotype 20, corresponding to areas of @entity32 and liquified @entity39 . Other inflammatory tissue lesions in the histological sections of the three genotypes were similar. Skeletal muscle tropism was higher than cardiac tropism in all the studied genotypes. All three genotypes shared parasite presence in skeletal muscle. Differences related to cardiac tropism were important: in genotype 19, 50% of studied stocks presented @entity9007 ; 20% in genotype 20 and 83% in genotype 39. Parasite presence in other tissues was scanty: in brain only in genotype 20 and in spleen and liver only in genotype 39. We found important histopathogenicity differences among the three studied genotypes, but they do not support the hypothesis of zymodeme pathogenic specificity due to the great diversity among stocks within each genotype.

title: Relationships between histopathological findings and phylogenetic divergence in XXXX .

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['colon, kidney and skeletal muscle']

entities_list: @entity1527 :: ('5693', 'Species') :: ['Trypanosoma cruzi', 'T. cruzi']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity1526 :: ('MESH:D014355', 'Disease') :: ["Chagas' disease"]

entities_list: @entity9007 :: ('MESH:D010192', 'Disease') :: ['pseudocysts']

answer: @entity1527 :: (5693,Species) :: ['Trypanosoma cruzi']


abstract: BACKGROUND: @entity2390 inhibits @entity1085 and prolongs intestinal transit. This leads to increases in the proportion of @entity6743 in, and @entity165 saturation of, gall bladder bile, factors that contribute to the pathogenesis of @entity2390 induced @entity5990 . AIMS: To see if an intestinal prokinetic, @entity4392 , could overcome these adverse effects of @entity2390 and if so, be considered as a candidate prophylactic drug for preventing @entity1085 . METHODS: A randomised, double blind, placebo controlled, crossover design was used to examine the effects of @entity4392 (10 mg four times daily) on @entity1085 , mouth to caecum and large bowel transit times, and the proportions of @entity6743 and other @entity3645 , in fasting serum from: (i) control subjects (n=6), (ii) acromegalic @entity1 not treated with @entity2390 (n=6), (iii) acromegalics on long term @entity2390 (n=8), and (iv) @entity1 with @entity1142 (n=8). RESULTS: @entity4392 had no prokinetic effect on the gall bladder. In fact, it significantly increased both fasting and postprandial gall bladder volumes. However, it @entity2133 to caecum (from 176 (13) to 113 (11) minutes; p<0.001) and large bowel (from 50 (3.0) to 31 (3.4) h; p<0.001) transit times. It also reduced the proportion of @entity6743 in serum from 26 (2.3) to 15 (1.8)% (p<0.001), with a reciprocal increase in the proportion of @entity6742 from 40 (3.5) to 51 (3.8)% (p<0.01). There were significant linear relationships between large bowel transit time and the proportions of @entity6743 (r=0.81; p<0.001) and @entity6742 (r=-0.53; p<0.001) in fasting serum. INTERPRETATION/SUMMARY: @entity4392 failed to overcome the adverse effects of @entity2390 on @entity1085 but it countered @entity2390 induced prolongation of small and large bowel transit. Therefore, if changes in intestinal transit contribute to the development of @entity2390 induced @entity1085 , enterokinetics such as @entity4392 may prevent their formation.

title: Effects of @entity4392 on XXXX , intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial.

entities_list: @entity4392 :: ('MESH:D020117', 'Chemical') :: ['Cisapride', 'cisapride']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1085 :: ('MESH:D005705', 'Disease') :: ['gall bladder emptying', 'iatrogenic gall bladder stones', 'gall bladder stones']

entities_list: @entity2133 :: ('MESH:D014987', 'Disease') :: ['shortened mouth']

entities_list: @entity5990 :: ('MESH:D042882', 'Disease') :: ['gall stones']

entities_list: @entity6742 :: ('MESH:D019826', 'Chemical') :: ['cholic acid']

entities_list: @entity2390 :: ('MESH:D015282', 'Chemical') :: ['octreotide', 'Octreotide']

entities_list: @entity3645 :: ('MESH:D001647', 'Chemical') :: ['bile acids']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

entities_list: @entity6743 :: ('MESH:D003840', 'Chemical') :: ['deoxycholic acid']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity1085 :: (MESH:D005705,Disease) :: ['gall bladder emptying']


abstract: BACKGROUND: @entity2390 inhibits @entity1085 and prolongs intestinal transit. This leads to increases in the proportion of @entity6743 in, and @entity165 saturation of, gall bladder bile, factors that contribute to the pathogenesis of @entity2390 induced @entity5990 . AIMS: To see if an intestinal prokinetic, @entity4392 , could overcome these adverse effects of @entity2390 and if so, be considered as a candidate prophylactic drug for preventing @entity1085 . METHODS: A randomised, double blind, placebo controlled, crossover design was used to examine the effects of @entity4392 (10 mg four times daily) on @entity1085 , mouth to caecum and large bowel transit times, and the proportions of @entity6743 and other @entity3645 , in fasting serum from: (i) control subjects (n=6), (ii) acromegalic @entity1 not treated with @entity2390 (n=6), (iii) acromegalics on long term @entity2390 (n=8), and (iv) @entity1 with @entity1142 (n=8). RESULTS: @entity4392 had no prokinetic effect on the gall bladder. In fact, it significantly increased both fasting and postprandial gall bladder volumes. However, it @entity2133 to caecum (from 176 (13) to 113 (11) minutes; p<0.001) and large bowel (from 50 (3.0) to 31 (3.4) h; p<0.001) transit times. It also reduced the proportion of @entity6743 in serum from 26 (2.3) to 15 (1.8)% (p<0.001), with a reciprocal increase in the proportion of @entity6742 from 40 (3.5) to 51 (3.8)% (p<0.01). There were significant linear relationships between large bowel transit time and the proportions of @entity6743 (r=0.81; p<0.001) and @entity6742 (r=-0.53; p<0.001) in fasting serum. INTERPRETATION/SUMMARY: @entity4392 failed to overcome the adverse effects of @entity2390 on @entity1085 but it countered @entity2390 induced prolongation of small and large bowel transit. Therefore, if changes in intestinal transit contribute to the development of @entity2390 induced @entity1085 , enterokinetics such as @entity4392 may prevent their formation.

title: Effects of XXXX on @entity1085 , intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial.

answer: @entity4392 :: (MESH:D020117,Chemical) :: ['cisapride']


abstract: OBJECT: The goal of this study was to investigate the risk of @entity1653 in relation to exogenous and endogenous sex hormones. METHODS: The study @entity1 were female registered nurses from 11 US states who were between 30 and 55 years of age when they enrolled in the Nurses' Health Study cohort. These @entity1 completed biennial questionnaires between 1976 and 1996. All @entity1 were free from @entity5 and other major medical illness at the onset of the study. The primary endpoint was @entity1653 as self-reported in biennial and supplemental questionnaires. During 1,213,522 @entity1 -years of follow-up review, 125 cases of @entity1653 were confirmed. After adjusting for age and body mass index (BMI), compared with postmenopausal @entity1 who had never used postmenopausal hormones, the relative risk (RR) for premenopausal @entity1 was 2.48 (95% confidence interval [CI] 1.29-4.77; p = 0.01) and the RR for postmenopausal @entity1 who received hormone therapy was 1.86 (95% CI 1.07-3.24; p = 0.03). The authors found no excess risk associated with past hormone use. In models that additionally controlled for hormone use and menopausal status, the authors found that, compared with @entity1 whose menarche occurred before they were 12 years of age, the RR for @entity1 whose menarche occurred at ages 12 through 14 years was 1.29 (95% CI 0.86-1.92; p = 0.21) and the RR for @entity1 whose menarche occurred after age 14 years was 1.97 (95% CI 1.06-3.66; p = 0.03). The authors also observed a tendency, albeit nonsignificant, for increased risk of @entity1653 in parous as opposed to nulliparous @entity1 (multivariate RR = 2.39, 95% CI 0.76-7.53; p = 0.14). A trend toward an increasing risk of @entity1653 with increasing BMI was also noted (p for trend = 0.06). No association was found for past or current use of oral contraceptives. CONCLUSIONS: The risk for @entity1653 was increased among @entity1 exposed to either endogenous or exogenous sex hormones. An unexpected relationship with increasing age at menarche was also noted; this remains unexplained.

title: Sex steroid hormone exposures and risk for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'person']

entities_list: @entity1653 :: ('MESH:D008579', 'Disease') :: ['meningioma', 'meningiomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

answer: @entity1653 :: (MESH:D008579,Disease) :: ['meningioma']


abstract: This study compared characteristics related to sexual history, sexual activities, sexual functioning, and @entity458 tendencies associated with sexuality in 45 young adults with @entity161 treated with novel neuroleptics and in 61 young adults from a comparison group. A smaller proportion of young adults with @entity161 currently had a sexual partner or had ever engaged in sexual relations. They also had @entity458 often. Whether affected by @entity161 or not, a smaller proportion of @entity1 had ever masturbated, and a smaller proportion of @entity1 currently had a sexual partner. @entity1 masturbated less often, felt @entity458 , and desired sexual relations less often, compared with @entity1 . Proportionally more @entity1 with @entity161 treated with @entity1090 or @entity1037 than @entity1 in the comparison group had at least one @entity250 , lacked sexual desire, and reported problems with sexual arousal and ejaculation. @entity1 with @entity161 were more likely to report problems with sexual arousal and @entity6726 , compared with @entity1 in the comparison group. Finally, young adults with @entity161 were more likely to develop negative @entity458 tendencies associated with sexuality than were young adults in the comparison group. Sexual problems are highly prevalent among young adults with @entity161 . Sexuality should occupy the space it deserves within psychosocial rehabilitation programs and the treatment of @entity161 .

title: Study of sexuality-related characteristics in young adults with XXXX treated with novel neuroleptics and in a comparison group of young adults.

entities_list: @entity250 :: ('MESH:D012735', 'Disease') :: ['sexual dysfunction']

entities_list: @entity6726 :: ('MESH:D005687', 'Disease') :: ['galactorrhea']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['psychological', 'less sexual desire', 'sexual relations and sexual desires less']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine']

entities_list: @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']

answer: @entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']


abstract: OBJECTIVE: The aim of this study was to identify clinical and pathologic characteristics of @entity1 with uterine @entity1377 (UPSC) who were all surgically managed at a single institution. The identified characteristics were then correlated with overall survival (OS). METHODS: One hundred twenty-nine @entity1 with FIGO stage I-IV UPSC who were surgically staged at the University of Texas M. D. Anderson @entity5 Center between 1989 and 2002 were identified. For each @entity1 , medical records and pathology reports were reviewed. The Kaplan-Meier method was used to generate OS data. Factors predictive of outcome were compared using the log-rank test and Cox regression analysis. RESULTS: There were 52 @entity1 with stage I disease, 5 with stage II, 41 with stage III, and 31 with stage IV. The median age at the time of diagnosis was 68 years (range, 44-93 years). A personal history of @entity0 was reported by 12.4% of the @entity1 , and a family history of @entity0 was reported by 16%. The 5-year OS among all @entity1 was 45.9%. Among the stage I @entity1 (IA, n = 19; IB, n = 26; and IC, n = 7), the 5-year OS was 62.9% (IA, 81.5%; IB, 58.6%; and IC, 34.3%). The 5-year OS for @entity1 with stage III and IV disease was 37.3 and 19.9%, respectively. Pathologic features predictive of OS included lymph node status (P </= 0.01), lymph vascular invasion (P </= 0.05), and depth of uterine invasion (P </= 0.05). Among @entity1 with no uterine invasion (n = 32), surgical staging revealed that 37% had stage III or IV disease. Among stage III @entity1 , those who received chemotherapy had a longer OS than those who did not receive chemotherapy (P = 0.03). CONCLUSION: In this population of nonselected @entity1 with UPSC, approximately 20% had a personal or family history of @entity0 . Stage, lymph node status, lymph vascular invasion, and depth of @entity3 were all risk factors for a worse prognosis. Traditional risk factors, however, did not predict the presence or the absence of @entity3 . Among @entity1 with noninvasive uterine disease, there was a high proportion with abdominal @entity3 . Therefore, complete surgical staging of these @entity1 is vital in determining their prognosis.

title: Uterine XXXX (UPSC): a single institution review of 129 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary serous carcinoma']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'myometrial invasion']

answer: @entity1377 :: (MESH:D002291,Disease) :: ['papillary serous carcinoma']


abstract: BACKGROUND: The hand-carried cardiac ultrasound (HCU) device is a recently introduced imaging device, which may be potentially useful in the primary care setting. AIM: To test the screening potential of a HCU for the detection of left ventricular (LV) dysfunction by evaluating LV ejection fraction (LVEF) and inferior vena cava (IVC) collapse. Standard echocardiographic @entity262 ( @entity262 ) and plasma @entity3876 ( @entity3876 ) measurements were used as a reference. METHODS: Eighty-eight consecutive @entity1 (56 male, aged 59+/-12 years) with suspected @entity1002 were enrolled in the study. The HCU-LVEF was visually estimated and the @entity262 -LVEF was derived by the Simpson's biplane method. A LVEF <40% represented @entity1002 . An IVC collapse of <50% and @entity3876 levels > or =15 pmol/l were considered abnormal. The correlation of HCU-LVEF, HCU-IVC and @entity3876 to the @entity262 -LVEF and @entity262 -IVC was analysed independently using 2x2 tables. RESULTS: Six @entity1 were excluded because of poor echo images. 19/82 @entity1 had @entity1002 . The HCU and @entity3876 could identify 17 and 18 out of these 19 @entity1 , respectively. The agreement for LVEF and IVC collapse between @entity262 and HCU was 96% for both parameters. The sensitivity of IVC collapse, HCU-LVEF and @entity3876 in identifying @entity1 with @entity1002 was 26, 89 and 94%, respectively. CONCLUSION: A HCU device can reliably be used as a screening tool for @entity1002 .

title: Screening for XXXX using a hand-carried cardiac ultrasound device.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3876 :: ('4879', 'Gene') :: ['BNP', 'brain natriuretic peptide']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['LV dysfunction']

answer: @entity1002 :: (MESH:D018487,Disease) :: ['left ventricular dysfunction']


abstract: OBJECTIVE: Sinus venosus type @entity118 (SVASD) differ from the secundum @entity118 by its location and high incidence of combination with other @entity299 , which inherently increases the risk of @entity260 . Right atriotomy is the most preferred approach for repairing the SVASD. @entity1817 or other rhythm disturbances can be observed. We compared the @entity260 between lateral cavatomy and right atriotomy in @entity1 who had SVASD. METHODS: Twenty-seven @entity1 who had SVASD (of 384 total ASDs) associated with partial @entity358 (PAPVC) underwent surgical repair during the period of January 1992 - December 2001 in G  lhane Military Medical Academy. Sinus venosus type @entity118 was repaired through right atrial incision by routine bi-caval cannulation in 14 @entity1 (Group 1) and repaired through lateral caval incision by direct caval cannulation in 13 @entity1 (Group 2). Lateral cavatomy was closed by pericardial patch in Group 2. We analyzed the relationship between incidence of rhythm disturbances and the technique in @entity1 who had SVASD with or without partial @entity358 prospectively. RESULTS: All @entity1 had a classical superior SVASD intraoperatively. Persistent @entity4264 (PLSVC) was observed in 5 @entity1 (Group 1=3 @entity1 , Group 2=2 @entity1 ). Postoperative mortality was seen in one @entity1 in Group 1 due to @entity3885 . In Group 1, one @entity1 underwent re-operation for upper and middle lobectomy of the right lung. Ambulatory Holter monitorizations were done in all @entity1 per 3 months periodically. In Group 1 @entity1817 was observed in 4 @entity1 and @entity955 was observed in 2 @entity1 , while in Group 2 only one @entity1 had @entity955 during follow-up period (p=0.037). CONCLUSION: Repair of SVASD in adult @entity1 is associated with low operative mortality and morbidity. The closure of the defect by pericardial patch is the most preferred technique but obstruction of caval veins can be seen. We suggest that posterior cavatomy can be preferred to atriotomy because of low incidence of @entity1817 and pulmonary or caval obstruction.

title: [The relationship between rhythm disturbances and incisions in adult sinus venosus XXXX ].

entities_list: @entity4264 :: ('MESH:D013479', 'Disease') :: ['left superior vena cava']

entities_list: @entity3885 :: ('MESH:D008173', 'Disease') :: ['pulmonary venous obstruction']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

entities_list: @entity1817 :: ('MESH:D012804', 'Disease') :: ['Postoperative sinus node dysfunction', 'sinus node dysfunction']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['anomalous pulmonary venous connection']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac anomalies']

entities_list: @entity118 :: ('MESH:D006344', 'Disease') :: ['atrial septal defects', 'atrial septal defect']

answer: @entity118 :: (MESH:D006344,Disease) :: ['atrial septal defects']


abstract: PURPOSE: To determine the prevalence and characteristics of @entity9 ( @entity9 ) in @entity1 with @entity2649 ( @entity2649 ) according to subgroup analysis of symptoms. MATERIALS AND METHODS: We prospectively enrolled subjects with @entity2649 (n=86) who were scheduled to undergo spinal surgery. The @entity1 were divided into two groups according to a chief complaint of @entity158 or @entity613 . We measured @entity1 's @entity158 score using the @entity227 ( @entity227 ), @entity717 ( @entity717 ) and Leads Assessment of Neuropathic Symptoms and Signs (LANSS). According to LANSS value, the prevalence of @entity9 component @entity158 in @entity1 with @entity2649 was assessed. Statistical analysis was performed to find the relationship between LANSS scores and the other scores. RESULTS: From our sample of 86 @entity1 , 31 (36.0%) had a @entity9 component, with 24 (63.4%) in the @entity158 group having @entity9 . However, only seven @entity1 (15.6%) in the @entity613 group had @entity9 . The LANSS @entity158 score was not significantly correlated with @entity227 scores for back @entity158 , but did correlate with @entity227 scores for @entity158 (R=0.73, p<0.001) and with @entity717 back @entity158 scores (R=0.54, p<0.01). CONCLUSION: One-third of the @entity1 with @entity2649 had a @entity9 component. The presence of @entity158 correlated strongly with @entity9 . The severity of @entity158 and @entity717 score were also closely related to a @entity9 component. This data may prove useful to understanding the @entity158 characteristics of @entity2649 and in better designing clinical trials for @entity9 treatment in @entity1 with @entity2649 .

title: XXXX Components in @entity1 with @entity2649 .

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual analog scale', 'VAS']

entities_list: @entity2649 :: ('MESH:C563613', 'Disease') :: ['lumbar spinal stenosis', 'LSS']

entities_list: @entity613 :: ('MESH:D007383', 'Disease') :: ['neurogenic claudication']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'leg pain', 'radicular pain']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['ODI', 'Oswestry Disability Index']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain', 'NP']

answer: @entity9 :: (MESH:D009437,Disease) :: ['Neuropathic Pain']


abstract: PURPOSE: To determine the prevalence and characteristics of @entity9 ( @entity9 ) in @entity1 with @entity2649 ( @entity2649 ) according to subgroup analysis of symptoms. MATERIALS AND METHODS: We prospectively enrolled subjects with @entity2649 (n=86) who were scheduled to undergo spinal surgery. The @entity1 were divided into two groups according to a chief complaint of @entity158 or @entity613 . We measured @entity1 's @entity158 score using the @entity227 ( @entity227 ), @entity717 ( @entity717 ) and Leads Assessment of Neuropathic Symptoms and Signs (LANSS). According to LANSS value, the prevalence of @entity9 component @entity158 in @entity1 with @entity2649 was assessed. Statistical analysis was performed to find the relationship between LANSS scores and the other scores. RESULTS: From our sample of 86 @entity1 , 31 (36.0%) had a @entity9 component, with 24 (63.4%) in the @entity158 group having @entity9 . However, only seven @entity1 (15.6%) in the @entity613 group had @entity9 . The LANSS @entity158 score was not significantly correlated with @entity227 scores for back @entity158 , but did correlate with @entity227 scores for @entity158 (R=0.73, p<0.001) and with @entity717 back @entity158 scores (R=0.54, p<0.01). CONCLUSION: One-third of the @entity1 with @entity2649 had a @entity9 component. The presence of @entity158 correlated strongly with @entity9 . The severity of @entity158 and @entity717 score were also closely related to a @entity9 component. This data may prove useful to understanding the @entity158 characteristics of @entity2649 and in better designing clinical trials for @entity9 treatment in @entity1 with @entity2649 .

title: @entity9 Components in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

answer: @entity2649 :: (MESH:C563613,Disease) :: ['Lumbar Spinal Stenosis']


abstract: PURPOSE: To determine the prevalence and characteristics of @entity9 ( @entity9 ) in @entity1 with @entity2649 ( @entity2649 ) according to subgroup analysis of symptoms. MATERIALS AND METHODS: We prospectively enrolled subjects with @entity2649 (n=86) who were scheduled to undergo spinal surgery. The @entity1 were divided into two groups according to a chief complaint of @entity158 or @entity613 . We measured @entity1 's @entity158 score using the @entity227 ( @entity227 ), @entity717 ( @entity717 ) and Leads Assessment of Neuropathic Symptoms and Signs (LANSS). According to LANSS value, the prevalence of @entity9 component @entity158 in @entity1 with @entity2649 was assessed. Statistical analysis was performed to find the relationship between LANSS scores and the other scores. RESULTS: From our sample of 86 @entity1 , 31 (36.0%) had a @entity9 component, with 24 (63.4%) in the @entity158 group having @entity9 . However, only seven @entity1 (15.6%) in the @entity613 group had @entity9 . The LANSS @entity158 score was not significantly correlated with @entity227 scores for back @entity158 , but did correlate with @entity227 scores for @entity158 (R=0.73, p<0.001) and with @entity717 back @entity158 scores (R=0.54, p<0.01). CONCLUSION: One-third of the @entity1 with @entity2649 had a @entity9 component. The presence of @entity158 correlated strongly with @entity9 . The severity of @entity158 and @entity717 score were also closely related to a @entity9 component. This data may prove useful to understanding the @entity158 characteristics of @entity2649 and in better designing clinical trials for @entity9 treatment in @entity1 with @entity2649 .

title: @entity9 Components in XXXX with @entity2649 .

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: @entity195 ( @entity195 ) involves multisystem @entity1333 of unknown origin. Ocular manifestations of @entity195 mostly include bilateral @entity5863 and @entity4816 , which are very challenging to treat. Interferon alfa-2a (IFN) has been recently introduced for treating refractory Beh  et @entity1596 , mainly in Germany and @entity233 . Nonetheless, there is so far no consensus about the ideal treatment regimen of IFN for Beh  et @entity1596 . We report our experience of IFN treatment in five Korean @entity195 @entity1 with refractory @entity1596 . All @entity1 @entity9645 ; one @entity1 had a positive pathergy test and 2 showed the presence of HLA-B51. Immunosuppressive agents used prior to IFN treatment included @entity205 and @entity1499 . The IFN treatment was commenced with a dose of 6-9 MIU/day for 7 days, adjusted according to individual ocular manifestations, tapered down to 3 MIU three times in a week, and then discontinued. All @entity1 showed positive response to IFN treatment; 50% of them showed complete response without additional major @entity32 during the follow-up period. @entity191 also improved after IFN treatment in most cases. After treatment, the relapse rate and the required dose of oral @entity228 were decreased in most cases, showing a significant @entity479 -sparing effect. However, the visual acuity was not improved in most cases due to irreversible macular sequelae. Despite the small sample size of this study, we suggest that, in Korean @entity1 , IFN is an effective treatment modality for @entity195 @entity1596 as was observed in German and Turkish @entity1 .

title: Clinical Experience of Interferon Alfa-2a Treatment for XXXX in Beh  et's Disease.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['ocular inflammation']

entities_list: @entity5863 :: ('MESH:D015864', 'Disease') :: ['panuveitis']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['vasculitis']

entities_list: @entity9645 :: ('MESH:D019226', 'Disease') :: ['complained of oral ulcers']

entities_list: @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ['Other BD symptoms']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ["Beh  et's disease", 'BD']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity4816 :: ('MESH:D031300', 'Disease') :: ['retinal vasculitis']

answer: @entity1596 :: (MESH:D014605,Disease) :: ['Refractory Uveitis']


abstract: OBJECTIVE: Pediatric radiotherapy is a day care procedure. In @entity1 , anaesthesia is necessary to prevent movement during the therapy. Traditionally intramuscular @entity3652 is used for these procedure because of its inherent safety in a @entity1 who used to be left alone in the cobalt room. METHODS: This study was designed to explore the efficacy of @entity1875 and @entity3652 in pediatric radiotherapy in nineteen @entity1 . The inclusion criteria was a @entity1 fasting for six hours with no fever or URTI in the past week. A @entity1 coming to the radiotherapy (RT) unit without an intravenous cannula was given intramuscular @entity3652 10 mg/kg and taken for the procedure. Before the @entity1 recovered from anaesthesia an intravenous cannula, 20-22G, Vasofix was inserted for subsequent sittings of RT. The @entity1 coming with an intravenous cannula was given @entity1875 2.5 mg/kg with @entity3303 (0.1 mg/kg) without @entity1425 . The parameters recorded were pulse rate, @entity26 saturation and respiratory rate-baseline to every 30 seconds till five minutes. Onset time, recovery time, oral feeding time and any untoward effects like @entity390 , @entity391 , nystagmus were also noted. RESULT: The drug was graded on a scale of 0-10 according to parental acceptability where 0 is the worst and 10 is the best acceptability. The mean (+/-SD) of all the measured parameters were calculated and compared between the two groups. CONCLUSION: @entity1875 was associated with faster onset, better recovery, early oral feeding time, no @entity390 and @entity391 and better parental acceptability. There was no @entity551 , @entity1168 and @entity26 saturation at 60 seconds, which was between 94-95%, was easily treatable with supplementation of @entity26 by face mask.

title: XXXX for pediatric radiotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'child']

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['adrenaline']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity3652 :: ('MESH:D007649', 'Chemical') :: ['ketamine']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['xylocaine']

entities_list: @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol', 'Propofol']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

answer: @entity1875 :: (MESH:D015742,Chemical) :: ['Propofol']


abstract: The report evaluates surgical drainage (SD) as a primary treatment of @entity4340 ( @entity4340 ). Seventy-two @entity1 , who underwent SD for @entity4340 at B P Koirala Institute of Health Sciences, Dharan, Nepal were studied. SD was performed through a lower abdominal, extra peritoneel, muscle splitting incision. Ultrasonography was used to diagnose the abscess in 53/54 @entity1 (98%). @entity794 was the most frequent organism grown in 45/65 @entity1 (69%). The mean duration of drainage was 3.2 +/- 1.4 days (range, 1-7 days). The treatment was successful in resolving the abscesses in all @entity1 . The mean hospital stay was 9.0 +/- 5.4 days (range, 3-40 days). Two @entity1 (2.8%) developed a recurrence, 10 months and 1 year after the operation, respectively. Another @entity1 developed an incisional @entity547 . There were no deaths. The average cost of treatment to the @entity1 was approximately Nepali rupees 2800 (US  40). Surgical drainage appears to be a cost-effective and safe treatment for @entity4340 .

title: Surgical drainage of XXXX --safe and cost-effective treatment.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity4340 :: ('MESH:D016659', 'Disease') :: ['PIA', 'primary iliopsoas abscess']

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus']

answer: @entity4340 :: (MESH:D016659,Disease) :: ['primary iliopsoas abscess']